

# **HHS Public Access**

Magn Reson Chem. Author manuscript; available in PMC 2016 August 01.

Published in final edited form as:

Author manuscript

Magn Reson Chem. 2015 August ; 53(8): 616-619. doi:10.1002/mrc.4254.

## New diketopiperazine dimer from a filamentous fungal isolate of Aspergillus sydowii

Amninder Kaur<sup>a</sup>, Huzefa A. Raja<sup>a</sup>, Blaise A. Darveaux<sup>b</sup>, Wei-Lun Chen<sup>c</sup>, Steven M. Swanson<sup>d</sup>, Cedric J. Pearce<sup>b</sup>, and Nicholas H. Oberlies<sup>a,\*</sup>

<sup>a</sup>Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, North Carolina 27402, United States

<sup>b</sup>Mycosynthetix, Inc., 505 Meadowlands Drive, Suite 103, Hillsborough, North Carolina 27278, United States

<sup>c</sup>Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois 60612, United States

<sup>d</sup>Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin - Madison, Madison, WI, 53705, United States

## **Graphical abstract**



### Keywords

NMR; <sup>1</sup>H NMR; <sup>13</sup>C NMR; Diketopiperazine; Fungi; Secondary metabolites

## Introduction

Prior investigations of filamentous fungi in our group have resulted in the isolation of several new and biologically active natural products.<sup>[1–3]</sup> Continuing these investigations, we have now analyzed the metabolites from a fungal isolate of *Aspergillus sydowii* (MSX19583) that was obtained from spruce litter collected in 1984 in Colorado, USA. The

Supporting Information Additional supporting information may be found in the online version of this article at the publisher's website.

<sup>\*</sup>Corresponding author. Tel.: +1 3363345474. nicholas\_oberlies@uncg.edu (N.H. Oberlies).

extracts from solid-substrate fermentation cultures exhibited cytotoxic activity against MDA-MB-435 (human melanoma) cells and were therefore pursued for further analysis. Chemical separation of the CH<sub>3</sub>CN/CH<sub>3</sub>OH extract afforded a new diketopiperazine dimer (1) in addition to three known compounds including cyclo-(*L*-phenylalaninyl-*L*-tryptophanyl) [2],<sup>[4, 5]</sup> *S*-sydonic acid (3), and *S*-sydonol (4) (Figure 1).<sup>[6]</sup>

## **Results and Discussion**

Compound 1 was assigned the molecular formula C<sub>40</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub> (Index of Hydrogen Deficiency of 26) based on the HRESIMS data. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of **1** displayed signals for only 18 protons and 20 carbons, respectively, suggesting a symmetrical dimeric structure (Table 1). The <sup>1</sup>H signals were attributed to nine aromatic protons, a pair of methylene units, three methine protons, and two exchangeable protons (Table 1; Figure S1). In addition to the <sup>13</sup>C NMR signals expected for the above structural features, one quaternary ( $\delta_C$  59.1, C-10), five non-protonated *sp*<sup>2</sup>-hybridized carbons [three aromatic ( $\delta_C$ 126.5, 135.6, and 150.1 for C-11, C-18, and C-16, respectively) and two carbonyl carbons  $(\delta_C 165.9, C-4 \text{ and } 168.7, C-7)$ ] were also observed (Table 1; Figure S2). Phenylalanine and tryptophan-derived subunits were readily identified after analysis of HSQC and HMBC NMR data (Figure 2). Presence of phenylalanine was also confirmed by amino acid analysis using Marfey's method.<sup>[7]</sup> HMBC correlations from H-6 ( $\delta_H$  5.45) to C-4, C-5 ( $\delta_C$  56.3), C-7, and C-8 ( $\delta_C$  58.9) supported the diketopiperazine ring system in **1**. A C–N covalent bond between C-2 and N-3 was identified by HMBC correlations from H-2 ( $\delta_H$  5.26) to C-8, C-9 ( $\delta_C$  35.4), C-11, and C-16. Finally, the monomeric units were linked at the only remaining position, C-10, thereby completing the gross structure of 1.

A search of the Dictionary of Natural Products<sup>[8]</sup> identified two compounds with identical molecular formulae, a symmetric diketopiperazine, WIN 64821, and an asymmetric analogue, asperazine.<sup>[9, 10]</sup> Although the gross structure of **1** was found to be similar to WIN 64821 after analysis of <sup>1</sup>H, <sup>13</sup>C, HSQC, and HMBC NMR data (Table 1 and Figure 2), the <sup>1</sup>H NMR signals for **1** were not fully consistent with those reported in the literature for WIN 64821 or a synthetic analogue, *ent*-WIN 64821,<sup>[11]</sup> suggesting differences in configuration. Four additional secondary metabolites with identical molecular formulae and structural skeletons are known in the literature; however, the lack of reported NMR data did not permit comparisons between these and **1**,<sup>[12, 13]</sup> which is a general challenge with this class of compounds.

The absolute configuration of **1** was determined using a suite of techniques. Analysis of the NOESY data for **1** did not provide sufficient information for complete assignment of the relative configuration. Marfey's method established the absolute configuration at C-5. Briefly, a sample of **1** was hydrolyzed in 6N HCl (110 °C; 24 h), and Marfey's derivative of the resulting phenylalanine standard sample was prepared using the methods reported previously.<sup>[7]</sup> HPLC analysis of the product ( $t_R = 5.06 \text{ min}$ ) and comparison with standards (L-Phe:  $t_R = 5.06 \text{ min}$  and D-Phe:  $t_R = 5.92 \text{ min}$ ) prepared in an analogous manner revealed the presence of L-phenylalanine. By analogy to compound **2**, the C-8 stereocenter was presumed to be an *S*-configuration based on biosynthetic considerations. Due to the limited number of protons, a NOESY correlation to assign the configuration at C-2 relative to other

configuration of **1** as shown (Figure 1). The extract of MSX19583 exhibited moderate cytotoxic activity (54% cell viability at 20  $\mu$ g/mL) against MDA-MB-435 human melanoma cells using procedures described in detail previously.<sup>[15–17]</sup> As such, compounds **1–4** were tested against two cancer cell lines, MDA-MB-435 and HT-29 (human colon cancer). All compounds were found to be inactive, displaying IC<sub>50</sub> values >20  $\mu$ M. Although the initial activity observed with the extract could not be attributed to the major compounds, it is possible that minor components present in trace amounts could contribute to the moderate cytotoxic effects. Also, various other biological activities have been reported for the known compounds isolated during this study.

accounted for the key difference between these compounds, supporting the absolute

For example, *S*-sydonol has been reported to have anti-diabetic and anti-inflammatory activities.<sup>[18]</sup> *R*-sydonol has been reported to show selective antibacterial activity against *Staphylococcus albus* and *Micrococcus tetragenus*, while *R*-sydonic acid exhibited broad spectrum activity against several species.<sup>[19]</sup> Cyclo-(*L*-phenylalaninyl-*L*-tryptophanyl) has been previously reported as a plant growth regulator.<sup>[4]</sup>

#### Experimental

#### **General experimental procedures**

Optical rotation data were acquired on a Rudolph Research Autopol III polarimeter (Rudolph Research Analytical, Flanders, NJ, USA). ECD data were collected using an Olis DSM 17 CD spectrophotometer (Olis, Bogard, GA, USA). UV data were obtained using a Varian Cary 100 Bio UV-vis spectrophotometer (Varian Medical Systems, Palo Alto, CA, USA). HRESIMS data were collected using an electrospray ionization (ESI) source coupled to a LTQ Orbitrap XL system (Thermo Fisher Scientific, San Jose, CA, USA) in positive and negative ionization modes via a liquid chromatography/autosampler system comprised of an Acquity UPLC system (Waters Corp., Milford, MA, USA). A CombiFlash Rf system using a 12 g RediSep Rf Si-gel Gold column (both from Teledyne-Isco, Lincoln, NE, USA) was employed for normal-phase flash column chromatography. High-performance liquid chromatography (HPLC) separations were performed utilizing Varian ProStar HPLC systems equipped with ProStar 210 pumps and a ProStar 335 photodiode array detector, using Galaxie Chromatography Workstation software (version 1.9.3.2, Varian Inc.). YMC ODS-A (Waters Corp.;  $5\mu$ m;  $250 \times 10$  mm for semi-preparative HPLC column) or Kinetex  $C_{18}$  (Phenomenex, Torrance, CA, USA; 5µm; columns of dimensions  $250 \times 21.2$  mm for preparative HPLC and 250 × 4.6 mm for analytical HPLC) were used for HPLC. For UPLC analysis, a BEH C<sub>18</sub> (Waters Corp.; 1.7  $\mu$ m; 50 × 2.1mm column) was used with data

collected and analyzed using Empower 3 software (Waters Corp.). The solvents were obtained from Fisher Scientific.

#### Fungal strain and fermentation

Mycosynthetix fungal strain MSX19583 (*Aspergillus sydowii*; See Supporting Information and Figure S5) was isolated from spruce litter collected in 1984 near Cumbres Pass, Colorado, USA at an elevation of 2985 m. A fresh culture of this isolate was grown on a malt extract slant, and a piece was transferred to a medium containing 2% soy peptone, 2% dextrose, and 1% yeast extract (YESD media). After incubation at 22 °C for 7 days (with agitation), the culture was used to inoculate 50 mL of rice medium [containing rice, vitamin solution and water (twice the volume of rice)] in a 250 mL Erlenmeyer flask. The culture was incubated at 22 °C until sufficient fungal growth (~ 14 d) was observed. The scaled-up culture was grown in a 2.8 L Fernbach flask containing 150 g of rice and 300 mL of H<sub>2</sub>O and inoculated using a seed culture grown in YESD medium followed by incubation at 22 °C for 14 d. Details for molecular identification and phylogenetic analysis of fungal strain MSX19583 can be found in the supporting information (Figure S5).

#### **Extraction and isolation**

To one Fernbach flask containing rice with fungal growth (MSX19583) was added 500 mL of 1:1 CH<sub>3</sub>OH/CHCl<sub>3</sub>. The culture was chopped with a spatula and shaken overnight (~16 h; rt) at ~100 rpm. After filtration, the remaining residues were washed with CH<sub>3</sub>OH. To the filtrate, 900 mL of CHCl<sub>3</sub> and 1.5 L of H<sub>2</sub>O were added. The mixture was stirred for 30 min and then transferred to a separatory funnel. The lower layer was drawn off into round-bottom flasks and evaporated to dryness. This dried material was re-constituted in 200 mL of 1:1 CH<sub>3</sub>OH/CH<sub>3</sub>CN and 200 mL of hexanes and transferred to a separatory funnel. The biphasic solution was shaken vigorously. The CH<sub>3</sub>OH/CH<sub>3</sub>CN layer was evaporated to dryness under vacuum to obtain 795 mg of the organic extract.

A portion of the organic extract (770 mg) was adsorbed onto a minimal amount of Celite 545 (Acros Organics, Geel, Belgium). After drying, the adsorbed mixture was loaded into a cartridge and subjected to normal-phase silica gel flash column chromatography (RediSep Rf Gold Si-gel column; 12g) using a step gradient with hexanes, CHCl<sub>3</sub>, and CH<sub>3</sub>OH (30 mL/min flow rate and 61.0 column volumes over 31.4 min). The resulting fractions were pooled according to UV and ELSD data to afford four fractions. Fraction three (80 mg) was subjected to preparative RP-HPLC (gradient elution using CH<sub>3</sub>CN in H<sub>2</sub>O (w 0.1% HCOOH): 40–80% for 20 min and 80–100% CH<sub>3</sub>CN for 10 min;  $\lambda = 210$  and 254 nm; flow rate = 21.2 mL/min) affording cyclo-(L-phenylalaninyl-L-tryptophanyl) [2; 1.2 mg, t<sub>R</sub> 4.0 min], 1 (3.0 mg, t<sub>R</sub> 7.5 min), S-sydonol (3; 2.4 mg, t<sub>R</sub> 9.7 min), and S-sydonic acid (4; 12.2 mg,  $t_{\rm R}$  10.5 min). Compounds 1 and 2 were further subjected to semi-preparative HPLC [isocratic elution using 50% CH<sub>3</sub>CN in H<sub>2</sub>O for 30 min in the case of **2** and 60% CH<sub>3</sub>CN in  $H_2O$  for 30 min in the case of 1; flow rate = 3 mL/min; YMC ODS-A (Waters Corp.; 5µm;  $250 \times 10$  mm)] affording 1.1 mg (t<sub>R</sub> 7.5 min) and 0.51 mg (t<sub>R</sub> 6.0 min), respectively. Purity was determined by UPLC using a gradient elution of 20% CH<sub>3</sub>CN in H<sub>2</sub>O (w 0.1% HCOOH) to 100% CH<sub>3</sub>CN over 3 min. All of the known compounds (2-4) were identified by comparison of their <sup>1</sup>H NMR, <sup>13</sup>C NMR, and/or MS data with literature values.<sup>[4-6]</sup>

Compound 1: White powder;  $[\alpha]^{23}_{D} -25 [c \ 0.04, 4:1 \ CH_3OH: (CH_3)_2SO], [\alpha]^{24}_{D} -343 [c \ 0.04, CH_2Cl_2]; UV/Vis (CH_3OH) <math>\lambda_{max}$  (log  $\varepsilon$ ) 303 (3.5), 245 (3.8), 218 (3.7) nm; ECD (50  $\mu$ M, CH<sub>3</sub>OH)  $\lambda_{max}$  ( $\varepsilon$ ) 303 (-18), 246 (-27), 226 (+12), 220 (+23) nm; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) data, see table 1; Key NOESY data: H-5  $\leftrightarrow$  H-6, H-17<sub>a</sub>, H-17<sub>b</sub>; H-8  $\leftrightarrow$  H-9<sub>a</sub>, H-9<sub>b</sub>; H-9<sub>a</sub>  $\leftrightarrow$  H-2; H-19/H-23  $\leftrightarrow$  H-6, H-17<sub>a</sub>, H-17<sub>b</sub>; HRESIMS obsd. *m*/z 665.2839 [M+H]<sup>+</sup> (calcd. for C<sub>40</sub>H<sub>37</sub>N<sub>6</sub>O<sub>4</sub>, 665.2871).

Cyclo-(*L*-phenylalaninyl-*L*-tryptophanyl) [**2**]: White powder;  $[\alpha]^{23}_D - 110$  (*c* 0.05, CH<sub>3</sub>OH); HRESIMS obsd. *m/z* 334.1548 [M+H]<sup>+</sup> (calcd. for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub>, 334.1550); <sup>1</sup>H NMR data were fully consistent with those reported in literature.<sup>[4, 5]</sup>

*S*-Sydonic acid (**3**): Colorless oil;  $[\alpha]^{23}_{D}$  +4 (*c* 1.22, CH<sub>3</sub>OH); HRESIMS obsd. *m/z* 249.1476 [M–H<sub>2</sub>O+H]<sup>+</sup> (calcd. for C<sub>15</sub>H<sub>21</sub>O<sub>3</sub>, 249.1485); <sup>1</sup>H NMR data were fully consistent with those reported in literature; structure was also confirmed by analysis of 2D NMR data.<sup>[6]</sup> *S*-Sydonol (**4**): Colorless oil;  $[\alpha]^{23}_{D}$  +6 (*c* 0.24, CH<sub>3</sub>OH); HRESIMS obsd. *m/z* 235.1684 [M–H<sub>2</sub>O+H]<sup>+</sup> (calcd. for C<sub>15</sub>H<sub>23</sub>O<sub>2</sub>, 235.1693); <sup>1</sup>H NMR data were fully consistent with those reported in literature.<sup>[6]</sup>

#### NMR data

NMR spectra (<sup>1</sup>H, <sup>13</sup>C, <sup>1</sup>H-<sup>13</sup>C HSQC, and <sup>1</sup>H-<sup>13</sup>C HMBC) were recorded at 25 °C in CDCl<sub>3</sub> on a JEOL ECS-400 NMR spectrometer (399.78 MHz for <sup>1</sup>H and 100.53 MHz for <sup>13</sup>C; JEOL Ltd., Tokyo, Japan) equipped with an auto tune 5 mm field gradient tunable Royal probe (NM-03810RO5/UPG). The <sup>1</sup>H and <sup>13</sup>C chemical shifts were referenced to the residual solvent peak of CDCl<sub>3</sub> at 7.24 ppm and 77.2 ppm, for proton and carbon, respectively. The <sup>1</sup>H sweep width was set at 5997 Hz for all experiments with a 90° pulse for <sup>1</sup>H of 6.4 µs and <sup>13</sup>C sweep width 25131 Hz with a 90° pulse for <sup>13</sup>C of 11.6 µs. The digital resolution of <sup>1</sup>H NMR was 0.37 Hz and that of <sup>13</sup>C NMR was 0.77 Hz. The edited-gradient <sup>1</sup>H-<sup>13</sup>C HSQC was acquired with <sup>13</sup>C sweep width of 16084 Hz and 256 t1 increments. Each increment was acquired with 16 transients. The one-bond coupling constant delay was set using 145 Hz and MPF8 decoupling was applied during acquisition. The gradient <sup>1</sup>H-<sup>13</sup>C HMBC was acquired using 64 transients per increment with 256 t1 increments. A sweep width of 20105 Hz was used for the <sup>13</sup>C dimension. One-bond coupling constant of 145 Hz and long-range coupling constant of 8 Hz were used to set the delays in the pulse sequence.

#### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

#### Acknowledgments

This research was supported by program project Grant P01 CA125066 from the National Cancer Institute/National Institutes of Health, Bethesda, MD, USA. Assistance from the staff of the NMR (Dr. Franklin J. Moy) and Mass Spectrometry (Dr. Brandie M. Ehrmann) Facilities at the University of North Carolina at Greensboro is gratefully acknowledged.

#### References

- El-Elimat T, Figueroa M, Raja HA, Adcock AF, Kroll DJ, Swanson SM, Wani MC, Pearce CJ, Oberlies NH. Tetrahedron Lett. 2013; 54:4300. [PubMed: 23956472]
- [2]. El-Elimat T, Figueroa M, Raja HA, Graf TN, Adcock AF, Kroll DJ, Day CS, Wani MC, Pearce CJ, Oberlies NH. J. Nat. Prod. 2013; 76:382. [PubMed: 23301853]
- [3]. Figueroa M, Raja H, Falkinham JO III, Adcock AF, Kroll DJ, Wani MC, Pearce CJ, Oberlies NH. J. Nat. Prod. 2013; 76:1007. [PubMed: 23806109]
- [4]. Kimura Y, Tani K, Kojima A, Sotoma G, Okada K, Shimada A. Phytochemistry. 1996; 41:665.
- [5]. Tullberg M, Grøtli M, Luthman K. Tetrahedron. 2006; 62:7484.
- [6]. Kudo S, Murakami T, Miyanishi J, Tanaka K, Takada N, Hashimoto M. Biosci. Biotech. Bioch. 2009; 73:203.
- [7]. Ayers S, Ehrmann BM, Adcock AF, Kroll DJ, Carcache de Blanco EJ, Shen Q, Swanson SM, Falkinham JO, Wani MC, Mitchell SM. J. Pept. Sci. 2012; 18:500. [PubMed: 22744757]
- [8]. Dictionary of Natural Products, Online 23.1. Taylor & Francis Group; London: 2014.
- [9]. Barrow CJ, Cai P, Snyder JK, Sedlock DM, Sun HH, Cooper R. J. Org. Chem. 1993; 58:6016.
- [10]. Varoglu M, Corbett TH, Valeriote FA, Crews P. J. Org. Chem. 1997; 62:7078. [PubMed: 11671801]
- [11]. Ovenden SP, Sberna G, Tait RM, Wildman HG, Patel R, Li B, Steffy K, Nguyen N, Meurer-Grimes BM. J. Nat. Prod. 2004; 67:2093. [PubMed: 15620260]
- [12]. Pérez-Balado C, Rodríguez-Graña P, de Lera ÁR. Chem.-Eur. J. 2009; 15:9928. [PubMed: 19681075]
- [13]. Hiramoto M, Miyata H, Shibazaki M, Saita Y. Symposium on the Chemistry of Natural Products. 1994; 557
- [14]. Springer JP, B chi G, Kobbe B, Demain AL, Clardy J. Tetrahedron Lett. 1977; 18:2403.
- [15]. Ayers S, Graf TN, Adcock AF, Kroll DJ, Matthew S, Carcache de Blanco EJ, Shen Q, Swanson SM, Wani MC, Pearce CJ. J. Nat. Prod. 2011; 74:1126. [PubMed: 21513293]
- [16]. El-Elimat T, Raja HA, Day CS, Chen WL, Swanson SM, Oberlies NH. J. Nat. Prod. 2014; 77:2088. [PubMed: 25093280]
- [17]. Alali FQ, Amrine CSM, El-Elimat T, Alkofahi A, Tawaha K, Gharaibah M, Swanson SM, Falkinham JO III, Cabeza M, Sánchez A. Phytochem. Lett. 2014; 9:96.
- [18]. Chung YM, Wei CK, Chuang DW, El-Shazly M, Hsieh CT, Asai T, Oshima Y, Hsieh TJ, Hwang TL, Wu YC. Bioorg. Med. Chem. 2013; 21:3866. [PubMed: 23647825]
- [19]. Li D, Xu Y, Shao CL, Yang RY, Zheng CJ, Chen YY, Fu XM, Qian PY, She ZG, de Voogd NJ. Mar. Drugs. 2012; 10:234. [PubMed: 22363233]



**Figure 1.** Structures of compounds **1–5**.



**Figure 2.** Key HMBC correlations for **1**.





Experimental ECD spectrum for **1** overlaid with ECD data reported for ditryptophenaline (**5**).

#### Page 10

## Table 1

 $^1H$  (400 MHz) and  $^{13}C$  NMR (100 MHz) data of 1 in CDCl3.

#	$\delta_{\rm H}$ (mult., J)	δ <sub>C</sub>	HMBC (H→ #C)
1, 1'	5.17 (s)		10, 11
2, 2'	5.26 (s)	78.9	8, 9, 11, 16
4, 4′		165.9	
5, 5′	4.15 (br d; 11.3)	56.3	4, 17, 18
6, 6′	5.45 (s)		4, 5, 7, 8, 17
7,7′		168.7	
8, 8'	3.87 (dd, 11.0, 5.9)	58.9	7, 9
9 <sub>a</sub> , 9′ <sub>a</sub>	2.67 (dd, 12.9, 11.0)	35.4	7, 8, 10, 11
9 <sub>b</sub> , 9′ <sub>b</sub>	2.56 (dd, 12.9, 5.9)		2, 8, 10, 11
10, 10′		59.1	
11, 11′		126.5	
12, 12′	7.20 (d, 7.6)	125.5	10, 14, 16
13, 13′	6.79 (t, 7.6)	119.6	11, 15
14, 14′	7.15 (m)	130.2	12, 16
15, 15′	6.65 (d, 7.9)	110.5	11, 13
16, 16′		150.1	
$17_{a}, 17'_{a}$	3.55 (dd, 14.4, 3.4)	36.7	4, 5, 18, 19/23
17 <sub>b</sub> , 17′ <sub>b</sub>	2.70 (dd, 14.4, 11.3)		4, 5, 18, 19/23
18, 18′		135.6	
19, 19′	7.15 (m)	129.1	17, 21, 23
20, 20′	7.32 (m)	129.6	18, 22
21, 21′	7.28 (m)	127.9	19/23
22, 22′	7.32 (m)	129.6	18, 20
23, 23'	7.15 (m)	129.1	17, 19, 21